Evidence mapPaperPMID 28609478Full record

ArticlePloS one2017

Purification of family B G protein-coupled receptors using nanodiscs: Application to human glucagon-like peptide-1 receptor.

Yingying Cai, Yuting Liu, Kelly J Culhane, Brian T DeVree, Yang Yang, Roger K Sunahara, Elsa C Y Yan

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. HDL and Therapy.Advances in experimental medicine and biology · 2022
    Article
  5. Article
  6. Functional Assembly ofBiomolecules · 2021
    Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Yingying CaiDepartment of Chemistry, Yale University, New Haven, Connecticut, United States of America.
Yuting LiuDepartment of Chemistry, Yale University, New Haven, Connecticut, United States of America.
Kelly J CulhaneDepartment of Molecular Biophysics and Biochemistry, Yale University, New Haven, Connecticut, United States of America.
Brian T DeVreeDepartment of Chemistry, University of Michigan, Ann Arbor, Michigan, United States of America.
Yang YangNanobiology Institute, Yale University, New Haven, Connecticut, United States of America.
Roger K SunaharaDepartment of Pharmacology, University of California at San Diego, La Jolla, California, United States of America.
Elsa C Y YanDepartment of Chemistry, Yale University, New Haven, Connecticut, United States of America.
Yale University · USUniversity of California, San Diego · USUniversity of Michigan–Ann Arbor · US

Funding

PREDOCTORAL PROGRAM IN BIOPHYSICST32GM008283 · YALE UNIVERSITY · 1988 to 2005
$2.5M
MICHIGAN MOLECULAR BIOPHYSICS TRAINING PROGRAMT32GM008270 · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 1988 to 2005
$1.8M
Structure and mechanism of beta2-adrenergic receptorR01GM068603 · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2003 to 2005
$975k
NIGMS NIH HHS DP2 GM114830NIGMS NIH HHS R01 GM068603NIGMS NIH HHS R01 GM083118NIGMS NIH HHS T32 GM008270NIGMS NIH HHS T32 GM008283
6 · The paper itself

Abstract

Family B G protein-coupled receptors (GPCRs) play vital roles in hormone-regulated homeostasis. They are drug targets for metabolic diseases, including type 2 diabetes and osteoporosis. Despite their importance, the signaling mechanisms for family B GPCRs at the molecular level remain largely unexplored due to the challenges in purification of functional receptors in sufficient amount for biophysical characterization. Here, we purified the family B GPCR human glucagon-like peptide-1 (GLP-1) receptor (GLP1R), whose agonists, e.g. exendin-4, are used for the treatment of type 2 diabetes mellitus. The receptor was expressed in HEK293S GnTl- cells using our recently developed protocol. The protocol incorporates the receptor into the native-like lipid environment of reconstituted high density lipoprotein (rHDL) particles, also known as nanodiscs, immediately after the membrane solubilization step followed by chromatographic purification, minimizing detergent contact with the target receptor to reduce denaturation and prolonging stabilization of receptor in lipid bilayers without extra steps of reconstitution. This method yielded purified GLP1R in nanodiscs that could bind to GLP-1 and exendin-4 and activate Gs protein. This nanodisc purification method can potentially be a general strategy to routinely obtain purified family B GPCRs in the 10s of microgram amounts useful for spectroscopic analysis of receptor functions and activation mechanisms.

Indexed as

Diabetes Mellitus, Type 2ExenatideGlucagon-Like Peptide 1Glucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsHEK293 CellsHumansHypoglycemic AgentsLipid BilayersLipoproteins, HDLMicroscopy, Electron, TransmissionNanostructuresNanotechnologyPeptidesProtein BindingReceptors, G-Protein-CoupledExenatideGlucagon-Like Peptide 1Glucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsLipid BilayersLipoproteins, HDLPeptidesReceptors, G-Protein-CoupledVenoms

Identifiers

PMID28609478
PMCPMC5469476
OpenAlexW2626126727

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.